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Summary: Recent cancer studies
emphasize that genetic and herita-
ble epigenetic changes drive the
evolutionary rate of cancer pro-
gression and drug resistance. We
discuss the ways in which nonher-
itable aspects of cellular variability
may significantly increase evolu-
tionary rate. Nonheritable variabili-
ty arises by stochastic fluctuations
in cells and by physiological re-
sponses of cells to the environ-
ment. New approaches to drug
design may be required to control
nonheritable variability and the
evolution of resistance to chemo-
therapy.
Cancer progression is a series of evolu-
tionary changes. Those changes include
enhanced cellular proliferation, reduced
cellular death by abrogating normal apo-
ptotic mechanisms, greater invasiveness by
increased expression of proteases, and
improved colonizing ability to achieve
metastasis [1]. In response to drug treat-
ment, cancer cells often evolve resistance
and continue to spread.
Each evolutionary step typically pro-
ceeds by acquisition of genetic or heritable
epigenetic changes in cells. When does the
novel genetic change arise in an evolu-
tionary step? By the current view, rare
genetic variants arise before widespread
phenotypic change. The idea is that a
novel phenotype always comes from a
novel genotype [2,3].
For example, rare resistant genetic
variants may exist before drug treatment
[4]. The drug selects those rare resistant
variants, killing the other cancer cells. In
progression, a genetic mutation may
abrogate apoptosis, allowing that genetic
clone to expand. Genotype leads to
phenotype leads to evolutionary change.
But does genotype always come before
phenotype in an evolutionary response
[5]? Consider the alternative in which
phenotype comes first, before any genetic
or heritable epigenetic change. In initial
drug treatment, cancer cells with the same
genotype may vary phenotypically with
regard to resistance. Nongenetic pheno-
typic variation arises by stochastic fluctu-
ations in cellular state or by cells respond-
ing physiologically to the changed
environment.
Some of the phenotypic variants may be
resistant, although not genetically or
heritably different from the susceptible
cells. In the absence of further treatment,
the surviving cells would eventually pro-
duce the same range of phenotypes as
before treatment. No evolutionary change
has occurred. With repeated treatment,
the novel selective pressure of the drug
treatment may eventually select a new
genetic variant among those initially
surviving cells. At that point, evolutionary
change occurs. Nongenetic phenotypic
variability eventually leads to acquisition
of a genetic variant and evolutionary
change.
Phenotypic variability may also come
before genetic variability during progres-
sion and metastasis. For example, in
metastatic colonization, a subset of phe-
notypically variable cells among a popula-
tion of genetically similar cells may survive
initially. Among those survivors, the novel
selective pressure of the new environment
may eventually favor a new genetic
variant, leading to evolutionary change.
It is certainly possible that nonherita-
ble phenotypic variants come before
genetic variants in cancer evolution. But
does it actually happen that way? And if
so, does it matter whether phenotypic or
genetic variants come first in evolutionary
progression and drug resistance? How
does the particular ordering influence
one’s understanding of progression and
the approaches one might use in treat-
ment?
Overview
In the past few years, many studies have
directly measured the nonheritable phe-
notypic variability in populations of cells
[6,7]. Several articles have argued that
nonheritable cellular variability may sig-
nificantly influence the evolution of drug
resistance or other key steps in cancer
progression [8–11]. However, mainstream
cancer research continues to emphasize
the primary role of genetic variants or
heritable epigenetic variants in initiating
the evolutionary changes of cancer pro-
gression and drug resistance. The current
literature on cellular variability, although
interesting, has yet to make a convincing
case for the fundamental role of nonher-
itable cellular variation in cancer.
We review some of the recent observa-
tions on cellular variability. We then
extend that prior work in two ways.
Essays articulate a specific perspective on a topic of
broad interest to scientists.
Citation: Frank SA, Rosner MR (2012) Nonheritable Cellular Variability Accelerates the Evolutionary Processes
of Cancer. PLoS Biol 10(4): e1001296. doi:10.1371/journal.pbio.1001296
Published April 3, 2012
Copyright:  2012 Frank, Rosner. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: SAF was supported by a Hogge-Baer Visiting Professorship in Cancer Research at the University of
Chicago, National Science Foundation grant EF-0822399, National Institute of General Medical Sciences MIDAS
Program grant U01-GM-76499, and a grant from the James S. McDonnell Foundation. MRR was supported by
National Institute of Health grant GM087630 and a Catalyst grant from the Chicago Biomedical Consortium.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: safrank@uci.edu
PLoS Biology | www.plosbiology.org 1 April 2012 | Volume 10 | Issue 4 | e1001296First, we use fundamental concepts of
evolutionary theory to show how nonher-
itable cellular variability likely plays a key
role in the evolutionary steps of cancer
progression and drug resistance. Nonher-
itable variability accelerates evolutionary
rate particularly strongly when popula-
tions experience intense competition or
face novel and extreme challenges for
adaptation [5]. That intensity of competi-
tion and extremeness of environmental
challenge characterize the evolutionary
steps in cancer progression and drug
resistance.
Second, we predict that cancer cells will
often evolve to express greater nonherita-
ble variability, because the evolutionary
changes of carcinogenesis, metastasis, and
drug resistance are more likely to occur in
cellular populations that express enhanced
variability.
Cellular Variability
Nonheritable variability takes two
forms. Stochastic cellular variability arises
from random fluctuations in the numbers
or functions of proteins. Phenotypic plas-
ticity arises from the response of cells to
the environment. Either form of variability
may allow a cell to express a novel
phenotype without genetic or heritable
epigenetic change. The initial expression
of phenotypic novelty accelerates subse-
quent heritable evolutionary changes. In
this section, we briefly describe examples
of cellular variability. In later sections, we
turn to more detailed discussion of the
evolutionary consequences.
Sigal et al. [12] measured stochastic
variability in protein levels in human cells.
They followed the dynamics of 20 proteins
in individual cells over several cellular
generations. They corrected for variations
between cells in the stage of the cell cycle.
After correction, the protein levels varied
between cells, with most standard devia-
tions between 15% to 30% of mean levels.
High protein levels in a particular cell
tended to decay over a few cellular
generations. This reversion to the mean
shows that cellular variability does not
arise from intrinsic differences between
cells. Instead, random fluctuations in
protein levels between cells create hetero-
geneity in the population.
Many earlier studies of bacteria dem-
onstrated stochastic variation in protein
levels and phenotypes [7]. Those earlier
studies, combined with the study by Sigal
et al. [12] and other experiments [6,13–
16], demonstrate the significant levels of
protein and phenotypic variability that
arise from random fluctuations of cellular
state. Those random fluctuations generate
nonheritable cellular variability.
Alternatively, cells with a common
heritable genome can generate different
phenotypes by their response to the
environment [17]. Changes in external
stresses and in signals from other cells
greatly alter cellular physiology and some-
times push cells to different developmental
states [18,19]. In a changed developmen-
tal state, a cell may take on the character-
istics of different tissues or of a stem cell
like proliferative capacity. In those altered
states, cells often change in their ability to
tolerate stress and to respond to signals for
proliferation or apoptosis. These types of
cellular plasticity potentially generate di-
verse and sometimes novel phenotypes
without underlying genetic or heritable
epigenetic change. The new nonheritable
phenotypes can initiate evolutionary
change [20], including resistance to drugs.
Resistance of Cancer Cells to
Chemotherapy
In the common theories of chemother-
apy, resistance arises from rare mutant
cells present before the start of treatment
[4,21]. Such preexisting genetic variation
for resistance is expected in large cellular
populations when single or double site
mutations confer resistance.
With a combination of drugs applied
simultaneously, the probability is very low
that any cell contains all of the genetic
variants necessary to protect against all of
the treatments. As in current HIV treat-
ment strategies [22,23], combination che-
motherapy minimizes the evolution of
resistance particularly well when multiple
mutations are needed for the initial
expression of resistance. However, three
recent studies of cancer find that, in
particular cases, the origin of resistance
begins with nonheritable cellular variation
instead of preexisting genetic variants (Box
1). Each study emphasized a different
mechanism that could generate nonheri-
table cellular variability: protein fluctua-
tion, cellular signaling state, or histone-
mediated alterations in cellular prolifera-
tion. Although these studies provide an
intriguing suggestion of broader issues in
the evolution of drug resistance, the role of
nonheritable variability has yet to be
integrated into widely understood concep-
tual or practical approaches to drug
treatment design [8–10].
These studies are important, because
initial drug treatments may be driving
tumors to genetically based stable resis-
tance by first selecting nonheritable phe-
notypes generated by cellular or tissue
variability. If so, we may need to rethink
approaches to treatment design. Before
turning to aspects of treatment, we first
explain how nonheritable variability ac-




To move forward, we need a clear
conceptual framework. How should the
recent results on nonheritable variability
in drug resistance be interpreted in
relation to genetic variability? What is
the broader significance in the context of
other evolutionary steps in carcinogenesis?
How should new experiments be designed
in light of the potential role of nonherita-
ble variability?
These questions are timely, because
new technologies provide the tools to
measure both genetic variability and
nonheritable aspects of cellular variability.
Those refined tools offer great opportuni-
ty, but we need clear principles to exploit
that technology and to gain a deeper
understanding of carcinogenesis and drug
resistance. Because the problems concern
evolutionary change of cells and tissues,
the principles arise from evolutionary
theory.
The idea that nonheritable phenotypic
variability accelerates evolutionary rate
has a long history. In cancer research,
Rubin [20] clearly described observa-
tions and concepts in which nonheritable
phenotypic variabilityi n i t i a t e sk e ys t e p s
in carcinogenesis. Rubin did not connect
his ideas to classical evolutionary theory,
instead roughly sketching out the logic as
a novel view of cancer evolution. Later
authors have repeated this argument for
drug resistance or, more generally, for
the evolutionary steps in the develop-
ment of cancer [8–11]. Those later
articles sometimes mention the literature
from evolutionary theory, but do not
develop that connection in a way that
leads to specific predictions or novel
insights.
Within the evolutionary literature,
many recent reviews discuss the relation
between nonheritable variation and evo-
lutionary rate. The extensive history goes
back to Baldwin [24] and includes several
subsequent theoretical refinements [5,25–
33]. For our purposes, we can start by
thinking of evolutionary adaptation as
analogous to the problem of searching
for an improved outcome in a complex
space of alternatives [34]. With regard to
cancer, ‘‘improved outcome’’ means mod-
ified cells or tissues that grow beyond
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outcompeting normal cells and tissues.
The key issue concerns how new traits
arise [5]. How does the evolving system of
cancer tissues find novel phenotypes that
improve competitive success and cause the
spread of the tumor? The search process
for evolutionary novelty can be divided
into short and long components that differ
by the degree of phenotypic change
required for cells and tissues to respond
to environmental challenges [32].
‘‘Short-range search’’ occurs when a
cellular clone expresses a variety of
phenotypes that differ by relatively small
changes, such as altering ligand binding or
modulating the pace of cell cycle progres-
sion. ‘‘Long-range search’’ occurs when
cells derived from a clone express pheno-
types that differ by relatively large chang-
es, such as altered developmental state,
tissue type, or other variant expression
unlikely to occur as a stochastic pheno-
typic fluctuation. Short-range and long-
range search play the role of discovery in
the evolutionary search for novel traits. In
addition to those two types of discovery
process, ‘‘local adaptation’’ by genetic
variation and selection refines the match
between existing traits and the environ-
ment.
The following sections discuss each of
these three components of evolutionary
variability and adaptation. Box 2 shows
how each component arises in the adap-
tive vertebrate immune system. Vertebrate
immunity provides the best-known biolog-
ical example of how the three aspects of
variability and adaptation combine to
determine the overall nature of evolution-
ary change. By studying vertebrate immu-
nity, one may gain insight into the
different processes of variability and ad-
aptation in cancer evolution.
Short-Range Search by Nonheritable
Stochastic Variability
Suppose, for example, that cells with an
altered signaling state can survive drug
treatment [35,36]. How does the altered
signaling state first arise? If a clone of cells
expresses a range of cellular signaling
states, then some cells may, by chance,
express a phenotype that can survive the
initial challenge. Those surviving cells
would not differ genetically from the killed
cells. Instead, each surviving cell would
produce daughter cells with roughly the
same distribution of phenotypes as the
initial cellular population. But those sur-
viving cells could subsequently acquire
genetic or heritable epigenetic variants
that tuned the signaling process to the
challenge of drug resistance.
The initial survival is by stochastic
variability of phenotype. That variability
is typically a short-range search, because
the phenotypes sampled must be produced
by a clone in which different cells express
fluctuations around the underlying herita-
ble type. Such fluctuations typically ex-
plore relatively nearby phenotypes, rather
than creating dramatically new pheno-
types.
Occasionally, a widely divergent phe-
notype may arise by fluctuations in
expression. But a widely divergent pheno-
type is likely to be rare, and a rare survivor
is unlikely to generate a population that
could accumulate the stabilizing genetic or
epigenetic changes needed for long-term
survival and adaptation. Thus, nonherita-
ble stochastic variability is most efficient at
promoting adaptation with respect to
favored phenotypes that are not too
distant from the current type [32].
Long-Range Search by Genetic
Variability or Physiological Plasticity
Certain environmental challenges re-
quire novel phenotypes that are unlikely to
arise by stochastic fluctuations and short-
range search. For example, metastatic
spread or new mechanisms of drug
resistance may often demand a novel
phenotype. The generation of long-range
novelty must be rare. However, such
novelty appears to occur in certain stages
of carcinogenesis and perhaps in certain
cases of resistance to drugs. How do such
long-range shifts in phenotype arise and
spread in populations in response to novel
and sometimes extreme environmental
challenge?
Genetic or stably heritable epigenetic
variants can cause major shifts in pheno-
type. A large cellular population inevitably
harbors many rare genetic variants. A
novel challenge may favor one of those
rare variants, allowing rapid adaptation to
arise from a preexisting pool of heritable
variants.
Alternatively, an altered environment
may induce expression of a significantly
altered phenotype [5,17]. Such physiolog-
ical plasticity in response to the environ-
ment can cause major shifts in phenotype.
Box 1. Drug Resistance Initiated by Nonheritable Cellular
Variability
Spencer et al. [14] showed that stochastic variability in protein levels and protein
states explained the observed cellular variability in survival when exposed to the
drug TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), which can
induce apoptosis in sensitive cells. Protein state is transmitted from mother to
daughter cells, causing transient heritability. However, new protein synthesis
causes a decay in heritability over a few cellular generations. Thus, the protein
fluctuation can initiate resistance in the absence of stably heritable variants, but
cannot by itself lead to widespread resistance. Subsequent genetic or stable
epigenetic change is needed after the initial resistance expressed by stochastic
cellular variability.
Although protein fluctuations correlate with cellular phenotype, the mechanisms
of phenotypic variability may be more closely associated with fluctuations in
states determined by signaling pathways. Singh et al. [35] measured heteroge-
neity in signaling states by colocalization patterns of activated signaling
molecules from microscopy images. In lung cancer cells, differences in cellular
signaling state correlate with the most sensitive and resistant populations in
response to the drug paclitaxel. This study established that a significant fraction
of the variability in signaling state was expressed by cells with a common
genotype, suggesting that stochastic fluctuations in signaling state may cause the
phenotypic heterogeneity in resistance.
Sharma et al. [36] observed small subpopulations of cells that survived treatment
by a variety of anticancer kinase inhibitor drugs. The resistant cells had an altered
chromatin state that depends on a particular histone demethylase. Drug tolerant
variants typically constituted about 0.3%–0.5% of the initial population. Those
cells that survive drug treatment are mostly quiescent. When those quiescent
cells are grown in the absence of drug, they resume growth and rapidly regain
drug sensitivity, demonstrating that resistance is a transient nonheritable
phenotype. If resistant, quiescent cells are exposed to continued drug treatment,
about 20% eventually resumed normal proliferation. Those proliferating cells
required about 90 doublings in drug-free passage to restore drug sensitivity,
suggesting that the nonheritable resistant state had become stabilized under
continued drug treatment.
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could drive cellular expression to a state
that is common for a different type of
tissue or a different stage in development.
Or a novel environment could induce a
phenotype not commonly expressed in
normal tissues, including extreme stress
responses or aberrant phenotypes arising
from novel environmental conditions.
Long-range changes in phenotype by
preexisting heritable variants or by envi-
ronmental induction may allow cells to
survive extreme or novel challenges.
Those cells that survive the initial chal-
lenge may then adapt by subsequent
nonheritable short-range search and by
acquiring heritable genetic and epigenetic
changes that enable local adaptation.
Local Adaptation
Short- and long-range search discover
novel phenotypes. In addition to discovery
of novelty, adaptation also depends on
small alterations to fine tune an existing
phenotype and improve success. For
example, if an aberrant tissue is already
competing with neighboring tissue for
limiting nutrients, an increase in the rate
of nutrient uptake may often be favored by
heritable variants that tune tissue physiol-
ogy. Similarly, if an aberrant tissue is
already secreting signals to attract com-
plementary stromal cells, heritable vari-
ants may improve the efficiency of signal
expression to attract stroma and enhance
the competitive success of the tissue. Or a
receptor may change slightly, preventing a
drug from binding to and entering the cell.
These sorts of tunings are a form of local
adaptation. The changes do not produce
novel characteristics, but instead improve




Understanding cancer progression and
drug resistance requires understanding the
evolutionary processes that change cellular
populations and tissues. We have empha-
sized three types of evolutionary process
that differ by the underlying cause of
phenotypic variability and by the amount
of phenotypic change required for cells
and tissues to respond to environmental
challenges. These three processes are not
mutually exclusive. In fact, the changes
required to achieve drug resistance or the
steps in carcinogenesis may often arise by
synergism between the different adaptive
processes.
Consider the problem of drug resis-
tance. In several studies, empirical evi-
dence suggests that preexisting genetic
variants provide the phenotypic variability
selected by novel drug-specific environ-
ments [4,21]. At the same time, we
described three experiments in which
nonheritable phenotypic fluctuations pro-
vide the phenotypic variability that allows
initial survival (Box 1). Many bacterial
studies also show that initial survival in the
presence of drugs depends on nonheritable
phenotypic variability [37–39].
How can we reconcile the evidence for
preexisting genetic variation with the
observations on nonheritable phenotypic
variability? Part of the answer is that, to
some extent, one finds what one is looking
for. Experimental designs that seek preex-
isting genetic variability will often find it,
and experimental designs that seek non-
heritable phenotypic variability will often
find it.
Focusing on preexisting genetic vari-
ability versus nonheritable phenotypic
variation may be a misleading contrast
[5]. Instead, we think that a natural
synergism occurs between the different
types of variability [32]. Nonheritable
physiological plasticity often provides a
type of long-range search, in which
extreme or novel environments induce
novel phenotypes. Preexisting genetic var-
iants can also generate novel phenotypes
in long-range search when the genetic
changes induce major phenotypic shifts.
By contrast, nonheritable stochastic fluc-
tuations often provide a type of short-
range search. The complex process of
Box 2. Synergism between Adaptive Processes in Vertebrate
Immunity
The mechanisms of antibody evolution in vertebrate immunity illustrate the
synergism between long-range search, short-range search, and local adaptation
[43,44]. In the development of the immune system, B-cell lineages undergo
programmed recombination early in life. That recombination yields numerous
genetically distinct clones. Each clone produces an antibody with a distinctive
pattern of binding affinities against different antigens. This initial generation of
genetic diversity is a type of long-range search that creates novel and widely
divergent phenotypes.
Each antibody type from this initial diversity tends to bind relatively weakly to a
distinct set of antigens. The broader the range of binding affinities for a particular
B-cell genotype, the more likely that the associated antibodies bind to a particular
antigen. In this regard, the broad but relatively weak binding affinities of the
original (natural) antibodies trade off the cost of weak binding for the benefit of a
phenotypically diverse response. The diverse binding creates a form of short-
range search spread over the binding propensity to a set of relatively similar
antigens. This short-range search is a form of nonheritable phenotypic variability,
because the different phenotypes arise from a common underlying genotype.
Although the diversity of binding affinities for a B-cell clone is itself heritable, the
binding of a particular B cell to a particular antigen does not heritably alter the
range of phenotypes expressed by a daughter cell. Therefore, the range of
binding affinities for a B-cell clone cannot by itself lead to evolutionary change
within the B-cell lineage.
Upon challenge with a foreign antigen, those B cells with matching antibodies are
stimulated to expand clonally. The B cells with initially weakly binding antibodies
then undergo a programmed round of hypermutation to the antibody binding
site and selection that favors those genetic variants that bind more tightly to the
foreign antigen. This affinity maturation produces tightly binding and highly
adapted antibodies in response to the novel challenge. Affinity maturation is the
process of local adaptation.
The ability of the adaptive immune system to respond to the huge diversity of
potential challenges depends on its synergism between genetic variability (long-
range search) and the broad but weak binding of antibodies from each B-cell
clone to a set of nearby antigens (short-range search). The initial natural
antibodies arise from genetically diverse clones produced by recombination. That
genetic diversity by itself could not cover the huge space of possible challenges.
It is the short-range nonheritable phenotypic variability around each genetic
variant that allows broad coverage against novel challenge. Once partial
recognition is achieved by the natural antibodies, the system can refine the
match locally by affinity maturation, which is a process of local adaptation by
heritable variation and selection.
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extreme or novel challenge may some-
times require both a long-range compo-
nent to create a phenotype somewhere
near a viable solution and a short-range
component to provide additional pheno-
typic variability that closely matches the
particular environmental challenge (Box
2).
Our main point is that genetic and
nonheritable phenotypic variation are not
alternatives. Rather, to understand the
complex evolutionary processes in drug
resistance and in the stages of carcinogen-
esis, one needs to consider the synergisms
between different aspects of evolutionary
search and adaptation.
Open Problems
We described three experiments in
which nonheritable phenotypic variability
played a key role in drug resistance (Box
1). Those experiments, along with the
theory we have developed, demonstrate
that nonheritable variability can be im-
portant. But how important and wide-
spread are the consequences of nonheri-
table variability? Study of the following
open problems may help to answer that
question.
Strategies of Drug Treatment
Current research on drug treatment of
cancer follows an analogy with successful
HIV combination therapy [22,23]. In an
individual infected with HIV, the large
viral population typically contains preex-
isting rare genetic variants resistant to any
single drug. Each additional simultaneous-
ly applied drug reduces the chance that a
single virus has all the necessary preexist-
ing resistance variants or can generate the
necessary mutations in the short time
before clearance by the drug. Optimal
treatment design comes down to choosing
the right number and combination of
simultaneously applied drugs to minimize
both resistance and toxic side effects.
In cancer treatment, combination ther-
apy has obvious benefits [40]. It will
almost always be more difficult for a
tumor to overcome additional simulta-
neously applied drugs. But the laboratory
observations on drug resistance through
nonheritable phenotypic variability raise
an important question. Should combina-
tion therapies be designed differently if the
origin of resistance sometimes comes from
nonheritable variability rather than preex-
isting genetic variants? The short answer is
that no one knows, partly because the
question is rarely asked.
Consider first why cancer may differ
from HIV. The HIV genome codes for
nine transcripts and fewer than 20 pro-
teins. The relation between genotype and
phenotype is relatively simple. An amino
acid substitution may, for example, alter
the binding dynamics of the drug to
replication enzymes or to proteases that
process HIV gene products [41]. Human
cells and tissues are far more complex
phenotypically. The same human genome
leads to all tissue types and to a wide range
of physiological responses. The potential
range of nonheritable phenotypic variabil-
ity for human cells and tissues is vastly
greater than for an HIV genotype.
Given the phenotypic range expressed
by a human cell through stochastic
fluctuations and in response to different
environments, how might one think about
alternative treatment strategies? The can-
cer cells that survive initial treatment may
be those that are particularly good at
responding to stressful environments by
upregulating any one of a number of
cellular stress responses, including cellular
quiescence. If so, then the best two-drug
treatment might be the combination of a
drug that stresses and often kills cells and a
stress response inhibitor that reduces the
chance that some cells may survive the
induced stress. In this case, the first drug
targets a gene in a key pathway. The
second drug targets a pathway that
generates the nonheritable phenotypic
variability that may allow initial survival
of cells in response to stress caused by the
first drug.
Homeostasis and Variability
Many evolutionary steps in carcinogen-
esis and drug resistance are evolutionary
responses to novel or extreme environ-
ments. Metastasis requires survival and
growth in a new environment. Certain
stages in carcinogenesis may require
tolerance to hypoxia or acidosis. Whenev-
er novel challenges arise that require
altered phenotypes to survive, those cells
and tissues that express a broader range of
phenotypes will often be favored.
Drugs, metastatic spread, and other
novel challenges select expression of in-
creased nonheritable variability, because
those cellular populations expressing a
broader range of phenotypes have a
greater chance of initial survival and
subsequent adaptation. Thus, over the
course of cancer progression and response
to drugs, tumor cells may often evolve to
express greater nonheritable phenotypic
variability.
The range of nonheritable variability is
itself a heritable trait. For example,
increased expression of variability may
arise from reducing or knocking out
normal, heritable homeostatic mecha-
nisms [42]. Reduced homeostasis is likely
to cause greater stochastic perturbations in
the expression of phenotype. Stochastic
perturbations enhance the rate of adapta-
tion when favored phenotypes are nearby,
in the sense discussed above in terms of
short-range search. These issues may lead
to some interesting experimental ap-
proaches (Box 3).
Another way to increase variability is to
respond more strongly to environmental
change. For example, cellular populations
that more easily change tissue type or
developmental state in response to an
altered environment also express greater
variability. Such variability through en-
hanced response to environmental change
increases the chance of success to novel
challenge. Large changes in phenotype in
response to novelty or stress enhance long-
range search and can greatly enhance
evolutionary rate.
The evolutionary challenges of carcino-
genesis and drug resistance likely favor
cellular populations with increased sto-
chasticity by reduced homeostasis and
increased capacity for environmental re-
sponsiveness. The associated nonheritable
phenotypic variability increases evolution-
ary rate by enhanced short-range and
long-range search.
Alternatively, certain challenges in car-
cinogenesis may favor reduced expression
of nonheritable phenotypic variability.
Suppose, for example, that rapid resource
acquisition and cell division allow cells to
outcompete neighbors. Expression of var-
iability to explore alternative phenotypes
would be a disadvantage, because those
phenotypes best tuned to the local condi-
tions win the race. Put another way, local
adaptation to a fixed environment often
favors a narrowing of phenotypic variabil-
ity, which may alter subsequent evolution-
ary response to novel challenges.
Synergism between Long-Range
and Short-Range Search
There is a natural tendency to dichot-
omize the problem of cancer evolution
into genetic mutations versus nonheritable
variability. Do we need to think mainly
about genetic variants, or does nonherita-
ble variability initiate the key steps of
carcinogenesis and resistance? However,
both the theory and the analogy with
vertebrate immunity (Box 2) suggest that a
more nuanced approach may be needed to
understand the evolutionary processes that
drive carcinogenesis, metastasis, and drug
resistance.
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tance to a particular drug requires preex-
isting mutations in the tumor population.
That fact does not exclude the importance
of nonheritable variability. As in verte-
brate immunity, the genetic variant may
bring the phenotype somewhere near what
is needed to survive. But actual survival
may require a physiological adjustment of
the mutated cells to the stress induced by
the drug. In this case, initial survival
depends on the synergism between the
mutation and an upregulated stress re-
sponse. Alternatively, there may be a
synergism between the mutation and some
other form of enhanced physiological
responsiveness.
There is no direct evidence for such
synergism, but few researchers are looking
for it. Drug resistance is an evolutionary
process, and evolutionary theory suggests
that such synergism would greatly enhance
the rate of adaptation to drug treatment.
So the notion of synergism is at least a
reasonable hypothesis that should be
studied.
Conclusions
The current cancer literature is domi-
nated by the view that genetic or stably
heritable epigenetic variants initiate the
key evolutionary changes in carcinogenesis
and drug resistance. Against that view, our
theme is that nonheritable cellular vari-
ability often plays a key role in initiating
the major evolutionary steps of carcino-
genesis and drug resistance.
The main point is that tumorigenesis
and drug treatment typically impose novel
Box 3. Nonheritable Variation in Drug Resistance: Experimental Approaches
Suppose, initially, that no cells have heritable resistance to a particular drug. To achieve heritable resistance, a cell must acquire
a genetic change or a stable epigenetic change. One possibility is a single mutation that prevents the drug from binding to its
target. Resistance by a single mutation is adaptation by a single jump. By contrast, if resistance requires multiple simultaneous
changes, adaptation by a jump from the susceptible to the resistant state becomes harder. In both cases, the difficulty is that
adaptation by a jump to a new phenotype may often be a rare event.
Now consider how the problem changes if we include nonheritable phenotypic variation. We use a numerical scale to give a
sense of the issues, although resistance phenotypes may not be aligned along a single quantitative dimension. Suppose the
initial susceptible genotype has an average phenotype of zero and a standard deviation of s, varying according to a normal
distribution. To achieve resistance, a cell must have a phenotype greater than three. If there is no phenotypic variation, s=0,
then no cells of the susceptible genotype are resistant. Resistance can only be achieved by a mutation that causes a phenotypic
jump above three. If s.0, then a fraction of the susceptible cells achieves resistance by having a phenotype above three. For
example, if s=1, then 0.1% of cells are resistant, if the standard deviation increases to s=2, then 6.7% of cells are resistant, and
if s=3, then 15.9% are resistant.
A rise in the variance increases the number of surviving cells. However, the more interesting issue is that a rise in the variance
changes the nature of the problem with respect to evolving a heritable increase in resistance. With no phenotypic variance,
s=0, heritable resistance requires a mutational jump to a phenotype greater than three. By contrast, if s=1, then a mutation
that increases mean phenotype from 0 to 0.1 raises the fraction of surviving cells from 0.135% to 0.187%; if s=2, then a
mutation that increases mean phenotype from 0 to 0.1 raises the fraction of surviving cells from 6.7% to 7.4%. Phenotypic
variance changes the nature of the adaptive problem. When there is no variance, a big heritable jump is needed. When there is
variance, small heritable changes in phenotype can be favored, allowing the population of cells to adapt gradually to the drug
challenge. Adaptation by small changes is generally easy and rapid, because small heritable variations are common. Adaptation
by large jumps is often hard and unpredictable, because the process depends on whether a mutation causing a big jump can
occur, and if so, how long one must wait for that mutation.
The theory is simple and, in the abstract, always true. But how the evolutionary process plays out in actual cellular populations
can be difficult to predict. The hard part is to figure out what the proper phenotypic dimension is for understanding the
adaptive problem. The experimental system with yeast developed by Levy and Siegal [42] provides a starting point. They
created many single-gene deletion strains and used high throughput techniques to measure morphological variation for each
deletion strain. They found that morphological variation increased in more than 300 of the single-gene deletion strains relative
to a base ‘‘wild-type’’ strain.
A similar approach might be used to analyze the fraction of cells resistant to a drug for various single-gene deletions. The
strains that have a relatively higher fraction of surviving cells may have increased phenotypic variance in the dimension that
influences survival to the challenge. One could then analyze in more detail the evolutionary response of those strains with
higher phenotypic variance, to determine if a resistance problem that initially required a large mutational jump had been
transformed into an adaptive problem that responds by the accumulation of many mutations each of small effect.
That scenario and experiment focus on phenotypic variation created by stochastic fluctuations around a mean value. We have
also emphasized that physiological responsiveness to novel environments can have a similar and often more powerful effect on
the dynamics of adaptation. Greater physiological responsiveness tends to speed adaptation by reducing the size of the
heritable phenotypic jumps needed to increase fitness. This problem is challenging experimentally, because one needs to find a
system in which physiological responsiveness itself varies with respect to the dimension of the environmental challenge
imposed by a selective process, such as a drug treatment. Perhaps a high throughput approach could be developed that is
similar in concept to that of Levy and Siegal. One could initially screen for the degree of responsiveness of cells to
environmental challenge. Then, one could follow with studies on the rate of evolution of drug resistance, comparing the
evolutionary rate between cells that have greater or less physiological responsiveness. That kind of study might identify the
characteristics of physiological responsiveness that are most important for the evolution of drug resistance, suggesting
alternative targets for therapy.
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cells and tissues. The rate of evolutionary
change in response to such challenges is
greatly enhanced by nonheritable pheno-
typic variability, often acting synergistical-
ly with genetic variability. A clear under-
standing of cancer and its treatment
requires closer attention to these funda-
mental evolutionary processes.
Our view has two important implica-
tions for drug treatment design. First, the
mechanisms of tumor resistance may
combine genetic mutations and nonheri-
table phenotypic fluctuations. If so, then
combinations of drugs should target both
the likely genetic resistance mutations and
the likely nonheritable resistance mecha-
nisms, rather than solely targeting genetic
mutations.
For example, a drug may target a
particular cellular protein. Resistance
may arise by a mutation in the targeted
cellular protein or by nonspecific stress
responses that compensate for the loss of
function of the targeted protein. Drug
combinations for both the targeted protein
and the nonspecific stress response may be
required. Alternatively, initial resistance to
a drug that targets a particular protein
may arise by nonheritable variability in
rate of cellular proliferation. A drug
combination that targeted the particular
protein and also reduced fluctuations in
cell cycle state may be effective.
The second implication for treatment
arises when drugs drive cellular popula-
tions to a resistant state via a nonheritable
intermediate state. For example, those
cells initially resistant to a treatment
may, by purely nonheritable phenotypic
fluctuation, express a greater stress re-
sponse than those cells that die. With
continued treatment, some of those ini-
tially resistant cells may subsequently
acquire a heritable change that upregu-
lates the stress response. Those mutated
cells will tend to increase, causing the
heritable fixation of a generalized resis-
tance mechanism. Subsequent alternative
drugs may then perform poorly. In this
case, initial drug combinations should
include stress response inhibitors.
In these two examples, we have men-
tioned stress response as a form of
nonheritable resistance. We chose that
response because it is easy to understand
how resistance to stress may enhance
resistance to drugs. However, our point
is more general. Any physiological mech-
anism that promotes nonheritable pheno-
typic variability in resistance tends to
enhance evolutionary rate, including the
rate at which stably heritable drug resis-
tance emerges. Closer attention to the
broad range of mechanisms that generate
nonheritable phenotypic variation is likely
to improve our understanding of resistance
and the design of combination treatments.
Acknowledgments
Robin Bush, Tim Fessenden, Carlo Maley, and
Robert Rosner provided helpful comments.
References
1. Hanahan D, Weinberg RA (2011) Hallmarks of
cancer: the next generation. Cell 144: 646–674.
2. Nowell PC (1976) The clonal evolution of tumor
cell populations. Science 194: 23–28.
3. Greaves M, Maley CC (2012) Clonal evolution in
cancer. Nature 481: 306–313.
4. Komarova NL, Wodarz D (2005) Drug resistance
in cancer: principles of emergence and preven-
tion. Proc Natl Acad Sci U S A 102: 9714–9719.
5. West-Eberhard MJ (2003) Developmental plas-
ticity and evolution. Oxford; New York: Oxford
University Press.
6. Suel GM, Kulkarni RP, Dworkin J, Garcia-
Ojalvo J, Elowitz MB (2007) Tunability and noise
dependence in differentiation dynamics. Science
315: 1716–1719.
7. Losick R, Desplan C (2008) Stochasticity and cell
fate. Science 320: 65–68.
8. Yang R, Niepel M, Mitchison TK, Sorger PK
(2010) Dissecting variability in responses to
cancer chemotherapy through systems pharma-
cology. Clin Pharmacol Ther 88: 34–38.
9. Altschuler SJ, Wu LF (2010) Cellular heteroge-
neity: do differences make a difference? Cell 141:
559–563.
10. Niepel M, Spencer SL, Sorger PK (2009) Non-
genetic cell-to-cell variability and the consequenc-
es for pharmacology. Curr Opin Chem Biol 13:
556–561.
11. Kaneko K (2011) Characterization of stem cells
and cancer cells on the basis of gene expression
profile stability, plasticity, and robustness: dy-
namical systems theory of gene expressions under
cell-cell interaction explains mutational robust-
ness of differentiated cells and suggests how
cancer cells emerge. Bioessays 33: 403–413.
12. Sigal A, Milo R, Cohen A, Geva-Zatorsky N,
Klein Y, et al. (2006) Variability and memory of
protein levels in human cells. Nature 444: 643–646.
13. Chang HH, Hemberg M, Barahona M,
Ingber DE, Huang S (2008) Transcriptome-wide
noise controls lineage choice in mammalian
progenitor cells. Nature 453: 544–547.
14. Spencer SL, Gaudet S, Albeck JG, Burke JM,
Sorger PK (2009) Non-genetic origins of cell-to-
cell variability in TRAIL-induced apoptosis.
Nature 459: 428–432.
15. Gupta PB, Fillmore CM, Jiang G, Shapira SD,
Tao K, et al. (2011) Stochastic state transitions
give rise to phenotypic equilibrium in populations
of cancer cells. Cell 146: 633–644.
16. Roesch A, Fukunaga-Kalabis M, Schmidt EC,
Zabierowski SE, Brafford PA, et al. (2010) A
temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor
growth. Cell 141: 583–594.
17. Bissell MJ, Hall HG, Parry G (1982) How does
the extracellular matrix direct gene expression?
J Theor Biol 99: 31–68.
18. Huang S, Eichler G, Bar-Yam Y, Ingber DE
(2005) Cell fates as high-dimensional attractor
states of a complex gene regulatory network. Phys
Rev Lett 94: 128701.
19. Huang S, Ernberg I, Kauffman S (2009) Cancer
attractors: a systems view of tumors from a gene
network dynamics and developmental perspec-
tive. Semin Cell Dev Biol 20: 869–876.
20. Rubin H (1990) The significance of biological
heterogeneity. Cancer Metastasis Rev 9: 1–20.
21. Chmielecki J, Foo J, Oxnard GR, Hutchinson K,
Ohashi K, et al. (2011) Optimization of dosing for
EGFR-mutant non-small cell lung cancer with
evolutionary cancer modeling. Sci Transl Med 3:
90ra59.
22. Larder BA, Kemp SD, Harrigan PR (1995)
Potential mechanism for sustained antiretroviral
efficacy of AZT-3TC combination therapy.
Science 269: 696–699.
23. Bonhoeffer S, May RM, Shaw GM, Nowak MA
(1997) Virus dynamics and drug therapy. Proc
Natl Acad Sci U S A 94: 6971–6976.
24. Baldwin JM (1896) A new factor in evolution.
American Naturalist 30: 441–451.
25. Waddington CH (1942) Canalization of develop-
ment and the inheritance of acquired characters.
Nature 154: 563–565.
26. Waddington CH (1953) Genetic assimilation of
an acquired character. Evolution 7: 118–126.
27. Schlichting CD, Pigliucci M (1998) Phenotypic
evolution: a reaction norm perspective. Sunder-
land, Massachusetts: Sinauer Associates.
28. Ancel LW (2000) Undermining the Baldwin
expediting effect: Does phenotypic plasticity
accelerate evolution? Theor Popul Biol 58:
307–319.
29. Price TD, Qvarnstrom A, Irwin DE (2003) The
role of phenotypic plasticity in driving genetic
evolution. Proc Biol Sci 270: 1433–1440.
30. Pigliucci M, Murren CJ, Schlichting CD (2006)
Phenotypic plasticity and evolution by genetic
assimilation. J Exp Biol 209: 2362–2367.
31. Lande R (2009) Adaptation to an extraordinary
environment by evolution of phenotypic plasticity
and genetic assimilation. J Evol Biol 22:
1435–1446.
32. Frank SA (2011) Natural selection. II. Develop-
mental variability and evolutionary rate. J Evol
Biol 24: 2310–2320.
33. Fierst JL (2011) A history of phenotypic plasticity
accelerates adaptation to a new environment.
J Evol Biol 24: 1992–2001.
34. Holland JH (1975) Adaptation in natural and
artificial systems. Ann Arbor: University of
Michigan Press.
35. SinghDK,KuCJ,WichaiditC,SteiningerRJ,3rd,
Wu LF, et al. (2010) Patterns of basal signaling
heterogeneity can distinguish cellular populations
with different drug sensitivities. Mol Syst Biol 6:
369.
3 6 .S h a r m aS V ,L e eD Y ,L iB ,Q u i n l a nM P ,
Takahashi F, et al. (2010) A chromatin-mediated
reversible drug-tolerant state in cancer cell
subpopulations. Cell 141: 69–80.
37. Kussell E, Kishony R, Balaban NQ, Leibler S
(2005) Bacterial persistence: a model of survival in
changing environments. Genetics 169: 1807–
1814.
38. Wiuff C, Zappala RM, Regoes RR, Garner KN,
Baquero F, et al. (2005) Phenotypic tolerance:
antibiotic enrichment of noninherited resistance
in bacterial populations. Antimicrob Agents Che-
mother 49: 1483–1494.
39. Lewis K (2007) Persister cells, dormancy and
infectious disease. Nat Rev Microbiol 5: 48–56.
40. Frei E, 3rd, Karon M, Levin RH, Freireich EJ,
Taylor RJ, et al. (1965) The effectiveness of
combinations of antileukemic agents in inducing
and maintaining remission in children with acute
leukemia. Blood 26: 642–656.
41. Zdanowicz MM (2006) The pharmacology of
HIV drug resistance. Am J Pharm Educ 70:
100.
PLoS Biology | www.plosbiology.org 7 April 2012 | Volume 10 | Issue 4 | e100129642. Levy SF, Siegal ML (2008) Network hubs buffer
environmental variation in Saccharomyces cerevi-
siae. PLoS Biol 6: e264. doi:10.1371/journal.pbio.
0060264.
43. Murphy KM, Travers P, Walport M (2007)
Janeway’s immunobiology. Boca Raton, Florida:
Garland Science.
44. Frank SA (2002) Immunology and evolution of
infectious disease. Princeton, New Jersey: Prince-
ton University Press.
PLoS Biology | www.plosbiology.org 8 April 2012 | Volume 10 | Issue 4 | e1001296